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Introduction. Melkersson–Rosenthal syndrome (MRS) is a neuromucocutaneous disorder characterized by the following classic
symptom triad: peripheral facial paralysis, orofacial edema, and scrotal or fissured tongue. It is rare, and since most of the patients
are oligo- or monosymptomatic, it makes it difficult to diagnose. Clinical Case. We present a 26-year-old male patient with a
history of sickle cell trait, untreated snoring, and left peripheral facial paralysis when he was 11 years old. +is was an overall 20-
day clinical profile that started with left peripheral facial paralysis, which was accompanied by moderate-intensity occipital
pulsatile headaches. Additionally, the patient experienced paresthesias in the tongue and feelings of labial edema. After one week,
he manifested peripheral facial paralysis on the right side. Physical examination revealed bilateral peripheral facial paralysis, mild
labial edema, and a scrotal or fissured tongue. +e patient received corticosteroids, which resulted in improvement of the edema
and facial paralysis.Discussion. MRS is a rare disorder that predominantly affects women, typically starting in their 20s or 30s.+e
etiology is unknown. However, a multifactorial origin that involves environmental factors and a genetic predisposition has been
proposed, which causes a dysfunction of the local immune system and autonomic nervous system (ANS) and an appearance of
granulomatous inflammation in the lips and tongue. Facial paralysis usually appears later on; however, it can occur from its
clinical debut. +ere are no curative treatments. +erapy is focused on modulating the patient’s immune response, and relapses
are frequent.
1. Introduction
Melkersson–Rosenthal syndrome (MRS) is a neuro-
mucocutaneous disorder without a known etiology. MRS is
characterized by a late onset of peripheral facial paralysis
with recurring incidences, orofacial edema, and a scrotal or
fissured tongue [1]. Even though MRS is rare and has a low
clinical presentation of 0.08% in the general population [2],
it is estimated that only 8–25% of the patients present the
classic symptom triad [3], making diagnosis difficult. Most
MRS patients have a monosymptomatic presentation of
reoccurring labial edema, which is also predominately found
in Miescher syndrome and Miescher’s cheilitis
granulomatosa [4]. We present a case of MRS in a male
patient who came with bilateral facial paralysis and who was
also diagnosed with sickle cell trait.
2. Clinical Case
+e patient is a 26-year-old Afro-Colombian male with a
history of sickle cell trait and left peripheral facial paralysis
from when he was 11 years old. He came for a 20-day clinical
profile development that started with feelings of weakness in
the right half of the face, causing difficulties in palpebral
closure. As a result, the patient experienced moderate-in-
tensity occipital pulsatile headaches that radiated to the
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mastoid process, feelings of paresthesias in the tongue, and
labial edema. +e following week, he started to manifest
contralateral weakness on one side of his face and the in-
ability for palpebral closure. +e physical exam showed
evidence of peripheral bilateral facial paralysis, House
Brackmann 2 on the left side and 3 on the right side, slight
labial edema, and a scrotal or fissured tongue (Figure 1). +e
blood analysis was normal, expect for sickle cell trait. +e
cerebral MRI did not present any alternations. +e patient
was treated with oral prednisolone for 7 days and resulted in
complete symptom improvement of his facial paralysis and
labial edema.
3. Discussion
Melkersson–Rosenthal syndrome (MRS) is a rare disorder
described for the first time in 1929 by Ernst Gustaf Mel-
kersson as peripheral facial paralysis and edema in the lips.
In 1931, Curt Rosenthal completed the classic symptom triad
by adding the presence of a scrotal or fissured tongue [1].
+is syndrome predominately affects women in a 2 :1 ratio,
usually starting in their 20s or 30s, and has a range of 1–69
years of age [3, 5]. +is clinical case presents a young adult
Afro-Colombian male patient. Ethnic distribution for MRS
has not been proven. Furthermore, more cases have been
reported in the United States and Europe, which could be a
misleading statistic according to some authors [6, 7].
+e etiology of MRS is unknown. However, a multi-
factorial origin that involves environmental factors and a
genetic predisposition has been proposed, which causes a
dysfunction of the local immune and autonomic nervous
system (ANS) [1, 8]. Multiple factors have been implicated in
its pathogenesis: infectious agents and allergic reactions to a
wide array of foods and dietary additives. +is includes
cobalt, monosodium glutamate, periodontal infections,
tonsillitis, adenoidal hypertrophy, orofacial infections due to
herpes type 1, and infections from influenza and myco-
bacteria [1, 5, 7]. +ere have been reports of familial oc-
currences that support a genetic etiology and autosomal
dominant mutations in genes such as FATP1 (fatty acid
transport protein) [9, 10]. +e tissue damage from MRS is
based on a noncaseating granulomatous inflammation in
epithelial cells, Langhans multinucleated giant cells, peri-
vascular lymphocytic infiltrate, and fibrosis [11]. +e pa-
ralysis has been related to pressure due to edema that passes
from the facial canal inside the temporal bone or the
granulomatous infiltration from the nerve [1].
+e clinical manifestations of MRS vary and are pre-
dominately monosymptomatic or oligosymptomatic (two
symptoms). According to different case series, only 25–75%
of patients with MRS present the classic symptom triad
[3, 5]. Facial paralysis is observed in 30–90% of cases and is
associated with orofacial edema that occurs in 13–50% of
patients [5]. Additionally, facial paralysis is usually the last
symptom to manifest, which can occur months or years after
the orofacial edema [7]. However, it can develop from its
clinical debut, which, almost always, is accompanied with
orofacial edema or a fissured tongue [3, 7]. Characteristi-
cally, facial paralysis develops within hours or days and is
always either partly or completely peripheral. Additionally,
the clinical course can be monophasic or recurring, with
possibilities of unilateral, bilateral, or alternating facial pa-
ralysis. As the clinical profile advances, facial paralysis can
become permanent [1]. In this clinical case, the patient
presented a bilateral facial paralysis. In a series of cases in
China, up to 58% of patients with MRS had bilateral facial
paralysis [12]. Peripheral bilateral facial paralysis is most
commonly caused by trauma, Guillain–Barré syndrome,
Bell’s palsy, sarcoidosis, and types of neoplasticism or in-
fectious meningitis [13].
Either in the form of facial edema, labial edema, or both,
orofacial edema is present in 70–80% of patients [3, 12],
making it the most common monosymptomatic presentation.
When labial edema is recurring, it is most often Miescher
syndrome or Miescher’s cheilitis granulomatosa [4]. +e
tongue alteration is present in 30–80% of cases [5] and has
been described as scrotal, geographic, fissured, or plicated. It
should be taken into account that the tongue alteration is
present in 5% of the population, which could make it con-
genital in 30–80% of patients and of diagnostic value only
when accompanied by the other two symptoms [7]. Other
clinical neurological manifestations of MRS depend on the
degree of inflammation and where structures are compro-
mised near the facial and other cranial nerves. Different
symptoms have been described, such as orolingual pares-
thesias, facial paresthesias, trigeminal neuralgia, weakness and
atrophy in the masticatory musculature, dysgeusia, dry eye,
hearing loss, vertigo, auricular pain, migraines predominately
in the occipital region, lingual weakness and atrophy, anos-
mia, dysphagia, and diplopia [3, 7, 14–16].
MRS has been associated with other manifestations that
are not neurological: lymphadenopathy, conjunctivitis,
uveitis, keratitis, blepharitis, and genital lesions [1, 17, 18]. In
addition, MRS has shown comorbid associations with
psoriasis, tobacco use, obesity, dyslipidemia, hypertension,
diabetes mellitus, migraines, gastrointestinal symptoms,
psychotic episodes, and obsessive-compulsive disorder
[1, 19, 20]. Some complications with the chronification of the
clinical profile have been noted, such as sinusitis, candidi-
asis, facial sun-rash, IgA nephropathy, vitiligo, and abnor-
malities in thyroid hormones [5].
Figure 1: Slight labial edema and a scrotal or fissured tongue.
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+e diagnosis of MRS is established during clinical
suspicion. +ere do not exist any recognized diagnostic
criteria nor a definitive clinical scoring guide. Some authors
suggest that the presence of the classic symptom triad of
recurring peripheral facial paralysis, orofacial edema, and a
scrotal or fissured tongue is sufficient for a diagnosis [2, 7].
Also, it has been proposed that there must be a minimum of
two symptoms in order to establish a clinical diagnosis,
requiring a biopsy in monosymptomatic cases such as with
Miescher cheilitis [4, 5]. A lip biopsy helps reinforce the
diagnosis by confirming a noncaseating granulomatous
inflammation [2, 11]. Other differential diagnoses are pri-
marily related to granulomatous disorders, such as Crohn’s
disease and sarcoidosis, that can overlap with many of the
classic triad of symptoms. Furthermore, diagnoses to con-
sider that can imitate mono- or oligosymptomatic presen-
tations are reactions to antibodies, recurring Bell paralysis,
Wegener’s vasculitis, amyloidosis, and infectious agents [21].
Complimentary exams should be conducted when the
clinical profile is confusing, the patient’s age is unusual in
relation to the start of their symptoms, they have an au-
toimmune history, or a lymphoproliferative disease [2].
Some exams that we recommend are glucose readings,
blood count, globular sedimentation rate, bran scan, brain
MRI, thorax X-ray, serum levels of the angiotensin-con-
verting enzyme, antibodies ANA and ANCA, and thyroid
tests. Other exams that are more specific to the clinical
profile are a colonoscopy, HLA for inflammatory bowel
syndrome, C1 inhibitor, and genetic tests [5]. Also, elec-
trodiagnostic tests, such as auditory evoked potentials, blink
reflex, electromyography, and neuroconduction of the facial
nerve, can complement the study. Some findings describe a
global or partial rate loss of the facial nerve branches, an
increase in distal latency, and a decrease of compound
muscular action potentials, which correlates with entrap-
ment neuropathy [22].
In the current case, immunological exams performed
were negative. +e only exam that resulted in an abnormal
reading was the sickle cell trait. In the literature, there has
not been a demonstrated association between MRS, sickle
cell anemia, and sickle cell trait. A biopsy of the lip was not
performed due to the presence of the classic clinical t as-
sociated to the characteristic clinical profile.
+ere does not exist a curative treatment. Pharmaco-
logical therapies are focused on modulating the immune
response, making corticoids the mainstay treatment. +ere
are not any clinical trials that suggest a type of corticoid or a
dosage. Using corticoid therapy has been shown to cause a
50–80% improvement in patients. +e treatment plan most
utilized is a full dosage of oral corticoids for a week and a
gradual reduction in the second week. In the most severe
cases, intravenous methylprednisolone is given [5].
In cases of persistent orofacial edema, some authors
suggest the use of intralesional corticoids, such as beta-
methasone and triamcinolone. Additionally, antibiotics with
anti-inflammatory properties, such as doxycycline and
minocycline, have been used as an adjuvant therapy [23, 24].
+e main indicator to implement immunosuppressors is the
comorbidity of an autoimmune system disease. Some case
series have shown benefits of using monoclonal antibodies
adalimumab and infliximab [5]. Other alternatives used are
dietary changes, avoiding possible allergenics and nutra-
ceuticals supplements [25]. Other medications such as anti-
inflammatories, steroids, and antihistamines have been
utilized to improve symptoms [26]. +e effectivity of the
pharmacological therapies is moderate and relapses occur
frequently. +e prognosis for permanent damage to the
facial nerve when there is recurring paralysis is poor in the
majority of the cases and is even worse in patients with
recurring Bell paralysis [27]. Surgical treatment is reserved
for patients with recurring facial paralysis and consists in the
decompression of the facial nerve by means of a mastoid-
ectomy. One study showed that none of the patients pre-
sented a recurrence of facial paralysis and about 90% of the
patients recovered to an almost normal functioning level
[28].
4. Conclusions
MRS is an infrequent disorder that is characterized by the
classic symptom triad of orofacial edema, facial paralysis,
and a fissured tongue but more commonly is mono- or
oligosymptomatic. In the absence of other clinical infor-
mation that points to another diagnosis, it is suggested that a
clinical diagnosis can be established when two or three
symptoms of the classic symptom triad are present. Occa-
sionally, bilateral facial paralysis can initially manifest and
should be considered in the broad range of the differential
diagnosis.
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and A. Krzeski, “Lower lip Oedema-Melkersson-Rosenthal
Syndrome or Cheilitis Granulomatosa,” New American
Journal of Otolaryngology Research, vol. 1, pp. 1-2, 2019.
[9] X. Xu, L. Guan, Y. Lv et al., “Exome sequencing identifies
FATP1 mutation in Melkersson-Rosenthal syndrome,” vol.
31, no. 5, Article ID e230, 2017.
[10] Y. Pei, G. M. Beaman, D. Mansfield, J. Clayton-Smith,
M. Stewart, and W. G. Newman, “Clinical and genetic het-
erogeneity in Melkersson-rosenthal syndrome,” European
Journal of Medical Genetics, vol. 62, no. 6, Article ID 103536,
2019.
[11] S. Bohra, P. B. Kariya, S. D. Bargale, and S. Kiran, “Clini-
copathological significance of Melkersson-Rosenthal syn-
drome,” BMJ Case Reports, vol. 2015, 2015.
[12] J.-J. Tang, X. Shen, J.-J. Xiao, and X.-P. Wang, “Retrospective
analysis of 69 patients with Melkersson-Rosenthal syndrome
in mainland China,” vol. 9, no. 2, pp. 3901–3908, 2016.
[13] R. A. Gaudin, N. Jowett, C. A. Banks, C. J. Knox, and
T. A. Hadlock, “Bilateral facial paralysis: a 13-year experi-
ence,” Plastic and Reconstructive Surgery, vol. 138, no. 4,
pp. 879–887, 2016.
[14] W. Zeng, S. Geng, X. Niu, and J. Yuan, “Complete Mel-
kersson–Rosenthal syndrome with multiple cranial nerve
palsies,” vol. 35, no. 3, pp. 272–274, 2010.
[15] M. U. Aluclu, U. Keklikci, A. Guzel, K. Unlu, and M. Tatli,
“Melkersson-Rosenthal syndrome with partial oculomotor
nerve palsy,” Annals of Saudi Medicine, vol. 28, no. 2,
pp. 135–137, 2008.
[16] R. Liu and S. Yu, “Melkersson-Rosenthal syndrome: a review
of seven patients,” Journal of Clinical Neuroscience, vol. 20,
no. 7, pp. 993–995, 2013.
[17] Z. Chu, Y. Liu, H. Zhang,W. Zeng, and S. Geng, “Melkersson-
Rosenthal syndrome with genitalia involved in a 12-year-old
boy,” Annals of Dermatology, vol. 28, no. 2, pp. 232–236, 2016.
[18] T. Ogawa, M. N. Sotto, and M. P. Hoang, “Granulomatous
dermatitis and others,” in Hospital-Based Dermatopathology:
An Illustrated Diagnostic Guide, M. P. Hoang andM. A. Selim,
Eds., pp. 137–198, Springer International Publishing, Cham,
Switzerland, 2020.
[19] G. Shalom, L. Bodner, and S. Halevy, “Melkersson-Rosenthal
Syndrome: the possible role of comorbidities in the etiopa-
thogenesis. Giornale italiano di dermatologia e venereologia:
organo ufficiale, Societa italiana di dermatologia e sifilografia,”
vol. 154, no. 3, pp. 347–351, 2019.
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